Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WILL-EMI: Emicizumab Prophylaxis in Type 3 Von Willebrand Disease
NCT06998524Phase 3Recruiting
- Sponsor
- Roche
- Start
- Jun 2025
- Primary completion
- Apr 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of emicizumab in von Willebrand disease type 3 (VWD3), sponsored by Roche. Started Jun 2025; status: recruiting.
02
Drugs
emicizumab
03
Conditions
von Willebrand disease type 3 (VWD3)
Beyond the preview
Go deeper on NCT06998524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06998524.